PeptideDB

Pericyazine

CAS: 2622-26-6 F: C21H23N3OS W: 365.49

Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term mana
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis[1]. Pericyazine is a selective D2-dopamine receptor antagonist[2][3]. Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects[4].
Target D2-dopamine receptor
In Vivo Studies in rodents show that Pericyazine is able to produce potentiation of ether and hexobarbital narcosis and morphine analgesia. It also has hypothermic activity and produces depression of spontaneous motor activity in mice. On a milligram potency basis, Pericyazine is more potent than chlorpromizine in the potentiation of barbiturate narcosis test and the blocking of conditioned avoidance in rats. Pericyazine demonstrates analgesic properties similar to methotrimeprazine in mice and rats and produces adrenergic blocking effects in mice and dogs[4].
Name Pericyazine
CAS 2622-26-6
Formula C21H23N3OS
Molar Mass 365.49
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7. [2]. Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [3]. Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. [4]. Cai HL, et al. A sensitive LC-MS/MS method for analysis of pericyazine in presence of 7-hydroxypericyazine and pericyazine sulphoxide in human plasma and its application to a comparative bioequivalence study in Chinese healthy volunteers. J Pharm Biomed A